SCHEDULE: Parvinder Singh Hyare Discloses 6.65% Stake in Galera

Parvinder Singh Hyare reports beneficial ownership of 13,521,921 shares of Galera Therapeutics following a mandatory conversion of Series B Preferred Stock.

Summary

• Parvinder Singh Hyare now holds 13,521,921 shares of Galera Therapeutics, Inc. common stock.
• This stake represents approximately 6.65% of the company's outstanding common stock.
• The shares were acquired through the mandatory conversion of 13,521.292 shares of Series B Non-Voting Convertible Preferred Stock on May 15, 2026.
• The reporting person has entered into a support agreement to vote in favor of the pending merger with Obsidian Therapeutics.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of ownership change resulting from a pre-planned corporate restructuring and merger support agreement.

Positives

• The reporting person has committed to supporting the proposed merger with Obsidian Therapeutics, signaling alignment with the board's strategic direction.
• The conversion of preferred stock into common stock simplifies the company's capital structure.

Negatives

• The company has waived previous obligations to hold a stockholder meeting regarding the conversion proposal, reducing direct shareholder oversight on that specific matter.
• The reporting person retains the right to sell or dispose of their significant stake, which could impact market liquidity and share price.

Risks

• The completion of the Obsidian Therapeutics merger is subject to various closing conditions and regulatory approvals.
• The reporting person may change their investment position at any time, potentially leading to future sales of common stock.
• General market and economic conditions may negatively impact the value of the investment.

Future Outlook

The reporting person intends to review their investment on a continuing basis and may purchase or sell shares depending on market conditions, the company's financial position, and the progress of the Obsidian merger.

Management Comments

• The reporting person has no present plans or proposals that relate to or would result in any of the matters set forth in subparagraphs (a) (j) of Item 4 of Schedule 13D, other than the support of the Obsidian merger.

Industry Context

StockSavvy.ai notes that this filing reflects the ongoing consolidation trend in the biotechnology sector, specifically highlighting the transition of Galera Therapeutics toward a merger with Obsidian Therapeutics.

Comparison to Industry Standards

• The use of support agreements by major shareholders is a standard practice in biotech M&A to ensure deal certainty.
• The conversion of preferred stock to common stock prior to a merger is a common mechanism to streamline equity structures for acquisition.

Corporate Governance

Stakeholder Impact

• Shareholders are impacted by the consolidation of ownership and the commitment of a major holder to the Obsidian merger.
• The conversion of preferred stock increases the total common share count, potentially diluting existing common shareholders.

Next Steps

• Completion of the merger with Obsidian Therapeutics.
• Ongoing review of investment position by the reporting person.

Key Dates

Keywords

Galera Therapeutics, Schedule 13D, Obsidian Therapeutics, Merger, Preferred Stock Conversion, Parvinder Singh Hyare